Our latest analysis of the ever evolving NSCLC landscape following BMS’s announcement on CheckMate-227
Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape
The changing face of renal cell cancer from several perspectives
A fresh look at a class of targeted therapy agents that are beginning to look promising in some cancer patients
Lessons learned from recent failure and a look at where a few new developments might be coming from...
On targeting immunosuppression and some obscure oncogenic targets
Are the PARPi a class effect or are there real differences between them that may become more apparent in future combo studies?
Beyond PD-1 and CTLA4 there are other checkpoint and IO targets being investigated. We take a look at one of the promising ones...
An in-depth look at Adaptimmune's TCR T cell therapy program
Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.
The latest part in our cytokine mini-series explores the potential for incorporating them in CARs or combining with checkpoint blockade through the lens of an expert in the field...
What can we learn from the updated Nektar NKTR-214 data presented at #ASCO18?
Update on TLR9 as a target and what we learn from the latest clinical data
Thoughts, reflections and learnings from the recent phase 3 lung cancer readouts from a lung cancer specialist...
Highlights and Lowlights amongst targeted therapy data at ASCO 2018
Ongoing discussion and debate about data in lung cancer and up and coming innate immunotherapies that may move the needle in IO-IO combos.
Dr Gilberto Lopes discusses the KEYNOTE 042 and 189 trials in first-line non-small cell lung cancer (NSCLC).
The promise and pitfalls of Day 1 of #ASCO18
We explore the importance of looking under the hood at various expression levels...
Not all IO-IO combos will be successful in solid tumours, what can we learn from the Genmab-Janssen news for daratumumab in NSCLC?
It’s a Bank Holiday weekend on both sides of the pond, which is always a good excuse for some…
Can TMB replace PD-L1 as a predictive biomarker of response for immune checkpoint blockade therapy?
A preview of key abstracts in urothelial and bladder cancer expected to be presented at ASCO18
What do we learn from the ASCO abstract release? Quite a lot! Here we debunk some of the controversial issues and inaccuracies that have arisen
Key themes and topics of interest in the poster halls - what stands out amongst several thousand posters?
What to watch out for at ASCO18 in the oral presentation sessions
How do we drive more T cells into the tumour? Here's one company who are looking to do just that.